Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seclidemstat - Salarius Pharmaceuticals

Next Previous
Drug Profile

Seclidemstat - Salarius Pharmaceuticals

Alternative Names: SP-2577; SP-2577 mesylate

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Utah Research Foundation
  • Developer M. D. Anderson Cancer Center; Salarius Pharmaceuticals; The Ivy Brain Tumor Center; Translational Genomics Research Institute
  • Class Antineoplastics; Benzoic acids; Hydrazines; Piperazines; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Chronic myelomonocytic leukaemia; Ewing's sarcoma; Myelodysplastic syndromes; Myxoid liposarcoma; Sarcoma; Solid tumours
  • Preclinical Adrenocortical carcinoma; Gynaecological cancer; Small cell lung cancer
  • No development reported Glioblastoma

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for preclinical development in Glioblastoma in USA (PO)
  • 03 Jan 2024 Updated efficacy data from a phase I/II trial in Ewing sarcoma and FET-rearranged sarcomas released by Salarius Pharmaceuticals
  • 30 Nov 2023 Salarius Pharmaceuticals in collaboration with M.D. Anderson Cancer Center resumes enrolment in its phase-I/II trial for Myelodysplastic syndromes in USA (NCT04734990)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top